Molecular characteristics for poor prognosis related renal cell carcinoma with lymph metastases
Genetic testing of kidney cancer tissue reveals which patients have aggressive tumors earlier, potentially guiding more aggressive upfront treatment decisions.
Multi-gene NGS of 81 RCC tissue samples (primary, lymph node, distant metastasis) from 52 patients reveals consistent genomic profiles between primary and metastatic foci, and identifies novel prognostic gene mutations (IGF2R, JUN, EPHA5, FH) associated with poor outcomes in lymph-metastatic RCC. The findings support NGS-based molecular staging as a complement to pathological staging for RCC prognosis.
What the study was
- Study design
- Retrospective observational, NGS
- Population
- Renal cell carcinoma patients with (n=31) and without (n=21) lymph node metastases, Peking University Third Hospital
- Sample size
- 52
- Category
- Genomics/Precision Medicine
- Maturity
- Exploratory
- Journal
- Beijing Da Xue Xue Bao Yi Xue Ban (Journal of Peking University. Health sciences)
Why it surfaced
Hypothesis-generating NGS study with novel prognostic markers in metastatic RCC; small n (52) and single-center limits score.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.